Accelrys Announces 2005 Product Launch
News May 05, 2005
Accelrys, has announced the launch of a number of next-generation products across its entire portfolio of software for pharmaceutical, chemical, and materials researchers.
Additionally, the company announced its Open Integration Platform, which will integrate Accelrys and SciTegic software in order to enable tailor-made, role-based solutions as well as enhanced intra- and inter-domain productivity. In this launch, Accelrys is introducing over 15 enhanced or new products.
According to Accelrys, among the highlights are new functionality for molecular biologists, new science for computational chemists, and enhanced platform support. "The launch of this latest suite of products from Accelrys shows our commitment to delivering new science and tools to our clients, extending the broadest & deepest product portfolio in the industry" said Mark J. Emkjer, president and CEO of Accelrys.
"By taking our point-products and identifying toolsets that can enable scientists and engineers in various disciplines, we aim to deliver solutions that address the priority requirements for our clients."
Accelrys continues to invest in its Discovery Studio (DS) line of products for life science research. This launch includes the latest release of DS GCG-a package of over 100 powerful sequence analysis tools for bioinformaticians.
Also included is DS MedChem Explorer, a tool for designing and optimizing lead compounds at the desktop that has now been enhanced with ADME/Tox models and support for Linux. DS ViewerPro, which provides desktop access to tools for generating, sharing, and analyzing high quality molecular information, now includes a 2D viewing option, as well as an automatic field fitting option for easier superimposition of molecules.
DS Accord for Excel, an Excel spreadsheet that allows display and calculation of chemical information, can now retrieve data from Oracle-based Accord Enterprise Informatics products through a simple-to-use data analysis wizard. QUANTA, Accelrys' software environment for X-ray crystallographers also features a Linux port and certification on IBM Thinkpads and IntelliStations running Red Hat Linux. Additionally, a number of new methods and algorithms have been added, including an automated model re-building method designed to substantially reduce model re-building time.
Insight II, a molecular modeling and simulation environment for protein modelers, computational chemists and structural biologists now allows seamless integration between Linux and IRIX. Insight II is also certified and optimized on IBM IntelliStations running Red Hat Linux. New science in Insight II includes a new protein-protein docking program called ZDOCKpro.
For chemists and screening biologists, Accord Enterprise Informatics (AEI) provides a solution for storing and managing drug discovery data. AEI now incorporates a new version of the Accord Chemistry Engine, which includes new calculators, Markush support, and enhanced stereochemistry support. Materials Studio (MS) Modeling, Accelrys' suite of modeling and simulation products for computational researchers in chemicals and materials R&D, has a number of important new features and upgrades.
New functionality is available for polymer chemists in the form of Blends - which allows calculation of miscibility for binary polymer and solvent systems. MS Modeling now features the first of set of tools derived for the current Accelrys Nanotechnology Consortium, including nano-builders.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE